CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

Elisa Becze BA, ELS


Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in theĀ Journal of Clinical Oncology.

View Article @

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles